PT-141
Bremelanotide
PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist originally derived from Melanotan II. Unlike PDE5 inhibitors, it acts centrally on MC4R pathways in the brain rather than on peripheral vasculature, which is why research has extended beyond erectile function into libido and arousal pathways in both sexes. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Research dosing is 1–2mg subcutaneously as needed. Researchers monitor blood pressure, testosterone, SHBG, and estradiol — blood pressure especially, since transient elevations are the most common side effect.
Typical dose
2mg
Cycle
As needed